Cargando…
Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial
All of the prospective multicenter trials that support the use of implantable defibrillators have used single chamber pacemakers/implantable cardiovertor defibrillators (ICDs). Despite the significantly increased cost of dual chamber pacemaker/ICD devices and the lack of outcome data, these devices...
Autor principal: | Wilkoff, Bruce L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59522/ https://www.ncbi.nlm.nih.gov/pubmed/11806799 http://dx.doi.org/10.1186/cvm-2-5-215 |
Ejemplares similares
-
Atrioventricular Cross-Talk Leading to Ventricular Pacing Inhibition in a Dual-Chamber ICD
por: Debie, Luuk, et al.
Publicado: (2011) -
Should all adjuvant breast cancer patients receive a bisphosphonate?
por: Cameron, David A
Publicado: (2003) -
Inappropriate Shocks in Patients with ICDs: Single Chamber versus Dual
Chamber
por: Gonçalves, Juliana, et al.
Publicado: (2013) -
Cardiac resynchronization therapy via left bundle branch area pacing and a dual-chamber ICD; a CROSS-LEFT substudy
por: Clementy, N, et al.
Publicado: (2023) -
Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing
por: Filippatos, Gerasimos, et al.
Publicado: (2017)